Maternini Matteo, Guttadauro Angelo, Avella Pasquale, Buondonno Antonio, Mascagni Domenico, Milito Giovanni, Stuto Angelo, Renzi Adolfo, Rennis Maria, Bottini Corrado, Quarto Gennaro, Nudo Raffaele, Del Re Luca, Amato Bruno, Gabrielli Francesco
General Surgery Department, Istituti clinici Zucchi of Monza, University of Milano-Bicocca, 20126, Milan, Italy.
Department of Medicine and Health Sciences "V. Tiberio," University of Molise, Via Francesco De Sanctis 1, 86100, Campobasso, Italy.
Open Med (Wars). 2023 Jul 11;18(1):20220553. doi: 10.1515/med-2022-0553. eCollection 2023.
Fistula in ano is a common anorectal disease in adults. Currently, surgery remains the definitive therapeutic approach, but in some cases, it can lead to serious complications as faecal or gas incontinence. Therefore, sphincter sparing treatments should be considered for complex fistulas. One of the sphincteric preserving treatment is the filling with a dermal extract commonly called "collagen glue" as Salvecoll-E gel. This is a multicentric, prospective, observational study on the use of Salvecoll-E gel in treatment of complex anal fistulas. We treated 70 patients from May 2016 to May 2017. In the first phase, we debrided the fistula tract using a loose seton kept for 4-6 weeks. In the second phase, the seton was removed and the fistula tract was filled with Salvecoll-E gel. In this article, we report results at 36 months of follow-up. Fifty patients (71.4%) had completely healed fistula within 36 months of follow-up. Twenty-eight patients (28.2%) had recurrences. Among these failures, 65% were within 6 months. All low transphincteric fistulas healed. Recurrences occurred only in median and high transphincteric fistulas. No patient had a worsening of continence status measured with Cleveland Clinic Florida Incontinence Severity score. Salvecoll-E gel is a recent finding among sphincter-sparing treatments. In this study, we demonstrate that it is a safe option in the treatment of complex fistulas. Final results are satisfactory and in line with the best results published in literature among mini-invasive treatments.
肛瘘是成人常见的肛肠疾病。目前,手术仍是确定性的治疗方法,但在某些情况下,可能会导致诸如粪便或气体失禁等严重并发症。因此,对于复杂肛瘘应考虑保留括约肌的治疗方法。其中一种保留括约肌的治疗方法是使用一种通常称为“胶原胶”(如Salvecoll-E凝胶)的真皮提取物进行填充。这是一项关于使用Salvecoll-E凝胶治疗复杂肛瘘的多中心、前瞻性观察研究。我们在2016年5月至2017年5月期间治疗了70例患者。在第一阶段,我们使用宽松的挂线清创瘘管,保留4至6周。在第二阶段,移除挂线,并用Salvecoll-E凝胶填充瘘管。在本文中,我们报告了36个月随访的结果。50例患者(71.4%)在随访的36个月内肛瘘完全愈合。28例患者(28.2%)复发。在这些治疗失败的患者中,65%在6个月内复发。所有低位经括约肌肛瘘均愈合。复发仅发生在中位和高位经括约肌肛瘘。没有患者的控便状态根据佛罗里达克利夫兰诊所失禁严重程度评分出现恶化。Salvecoll-E凝胶是保留括约肌治疗方法中的一项新发现。在本研究中,我们证明它是治疗复杂肛瘘的一种安全选择。最终结果令人满意,与微创治疗文献中公布的最佳结果一致。